T D Ecke

Summary

Publications

  1. ncbi request reprint Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation
    Thorsten H Ecke
    Department of Urology, HUMAINE Hospital Bad Saarow, Germany
    Anticancer Res 25:635-41. 2005
  2. pmc External validation of an artificial neural network and two nomograms for prostate cancer detection
    Thorsten H Ecke
    Department of Urology, HELIOS Hospital, 15526 Bad Saarow, Germany
    ISRN Urol 2012:643181. 2012
  3. doi request reprint Outcome prediction for prostate cancer detection rate with artificial neural network (ANN) in daily routine
    Thorsten H Ecke
    Department of Urology, HELIOS Hospital, Bad Saarow, Germany
    Urol Oncol 30:139-44. 2012
  4. pmc Idiopathic giant abdominal lymph cyst: a case report
    Thorsten H Ecke
    HELIOS Hospital, Department of Urology, Bad Saarow, Germany
    J Med Case Reports 5:21. 2011
  5. ncbi request reprint Does a new ultrasound probe change the complication rates of transrectal ultrasound-guided needle biopsies of the prostate?
    Thorsten H Ecke
    Department of Urology, HELIOS Hospital, Pieskower Strasse 33, D 15526 Bad Saarow, Germany
    Anticancer Res 30:3071-6. 2010
  6. doi request reprint Evaluation of symptoms and patients' comfort for JJ-ureteral stents with and without antireflux-membrane valve
    Thorsten H Ecke
    Department of Urology, HELIOS Hospital, Bad Saarow, Germany
    Urology 75:212-6. 2010
  7. ncbi request reprint Gemcitabine, paclitaxel, and cisplatin as combined adjuvant approach in transitional cell carcinoma of the urothelium
    T D Ecke
    HELIOS Hospital, Department of Urology, Pieskower Strasse 33, D 15526 Bad Saarow, Germany
    Minerva Urol Nefrol 61:249-56. 2009
  8. ncbi request reprint Palliative chemotherapy with gemcitabine, paclitaxel, and cisplatin as first-line treatment following gemcitabine monotherapy for patients with transitional cell carcinoma of the urothelium
    T H Ecke
    Department of Urology, HELIOS Hospital, Bad Saarow, Germany
    Minerva Urol Nefrol 61:1-8. 2009
  9. pmc Multimodal stone therapy for two forgotten and encrusted ureteral stents: a case report
    Thorsten H Ecke
    Department of Urology, HELIOS Hospital, Pieskower Str 33, Bad Saarow 15526, Germany
    Cases J 2:106. 2009
  10. ncbi request reprint Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium
    Thorsten H Ecke
    Department of Urology, HELIOS Hospital, D 15526 Bad Saarow, Germany
    Oncol Rep 16:1381-8. 2006

Detail Information

Publications19

  1. ncbi request reprint Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation
    Thorsten H Ecke
    Department of Urology, HUMAINE Hospital Bad Saarow, Germany
    Anticancer Res 25:635-41. 2005
    ..Mutations of the tumour suppressor gene P53 (TP53) are frequently correlated with tumour development and progression. We compared TPA, HER-2/neu and uPAR, and TP53 mutation in tumour-free and bladder cancer patients...
  2. pmc External validation of an artificial neural network and two nomograms for prostate cancer detection
    Thorsten H Ecke
    Department of Urology, HELIOS Hospital, 15526 Bad Saarow, Germany
    ISRN Urol 2012:643181. 2012
    ..The worth of multivariate models is limited when external validations were performed without knowledge of the circumstances of the model's development...
  3. doi request reprint Outcome prediction for prostate cancer detection rate with artificial neural network (ANN) in daily routine
    Thorsten H Ecke
    Department of Urology, HELIOS Hospital, Bad Saarow, Germany
    Urol Oncol 30:139-44. 2012
    ....
  4. pmc Idiopathic giant abdominal lymph cyst: a case report
    Thorsten H Ecke
    HELIOS Hospital, Department of Urology, Bad Saarow, Germany
    J Med Case Reports 5:21. 2011
    ..abstract:..
  5. ncbi request reprint Does a new ultrasound probe change the complication rates of transrectal ultrasound-guided needle biopsies of the prostate?
    Thorsten H Ecke
    Department of Urology, HELIOS Hospital, Pieskower Strasse 33, D 15526 Bad Saarow, Germany
    Anticancer Res 30:3071-6. 2010
    ..Transrectal ultrasound-guided prostate needle biopsies are performed to diagnose prostate cancer. This study prospectively evaluated the safety, morbidity and complication rates with two different ultrasound probes...
  6. doi request reprint Evaluation of symptoms and patients' comfort for JJ-ureteral stents with and without antireflux-membrane valve
    Thorsten H Ecke
    Department of Urology, HELIOS Hospital, Bad Saarow, Germany
    Urology 75:212-6. 2010
    ..To evaluate safety and patients' comfort by using the ureteral stent symptom questionnaire. Ureteral stents are used to provide upper urinary-tract drainage...
  7. ncbi request reprint Gemcitabine, paclitaxel, and cisplatin as combined adjuvant approach in transitional cell carcinoma of the urothelium
    T D Ecke
    HELIOS Hospital, Department of Urology, Pieskower Strasse 33, D 15526 Bad Saarow, Germany
    Minerva Urol Nefrol 61:249-56. 2009
    ..The objective of this study was to evaluate the adjuvant chemotherapy with gemcitabine, paclitaxel, and cisplatin for urothelial carcinoma...
  8. ncbi request reprint Palliative chemotherapy with gemcitabine, paclitaxel, and cisplatin as first-line treatment following gemcitabine monotherapy for patients with transitional cell carcinoma of the urothelium
    T H Ecke
    Department of Urology, HELIOS Hospital, Bad Saarow, Germany
    Minerva Urol Nefrol 61:1-8. 2009
    ..The objective of this study was to evaluate the palliative chemotherapy with gemcitabine, paclitaxel, and cisplatin for transitional cell carcinoma...
  9. pmc Multimodal stone therapy for two forgotten and encrusted ureteral stents: a case report
    Thorsten H Ecke
    Department of Urology, HELIOS Hospital, Pieskower Str 33, Bad Saarow 15526, Germany
    Cases J 2:106. 2009
    ..abstract:..
  10. ncbi request reprint Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium
    Thorsten H Ecke
    Department of Urology, HELIOS Hospital, D 15526 Bad Saarow, Germany
    Oncol Rep 16:1381-8. 2006
    ..This treatment should be considered as a suitable option that deserves further prospective evaluation. The ECOG performance status is an important predictive factor for survival...
  11. ncbi request reprint TP53 mutation in prostate needle biopsies--comparison with patients follow-up
    Thorsten H Ecke
    HELIOS Hospital, Department of Urology, Pieskower Strasse 33, D 15526 Bad Saarow, Germany
    Anticancer Res 27:4143-8. 2007
    ....
  12. doi request reprint Body mass index (BMI) and mutations of tumor suppressor gene p53 (TP53) in patients with urinary bladder cancer
    Thorsten H Ecke
    Department of Urology, HELIOS Hospital, Bad Saarow, Germany
    Urol Oncol 26:470-3. 2008
    ..Mutations of TP53 are frequently correlated with tumor development and progression. We evaluated the effect of body mass index (BMI) and mutation status of tumor suppressor gene p53 (TP53) on patients with urinary bladder cancer...
  13. doi request reprint Complications and risk factors of transrectal ultrasound guided needle biopsies of the prostate evaluated by questionnaire
    Thorsten H Ecke
    Department of Urology, HELIOS Hospital, Bad Saarow, Germany
    Urol Oncol 26:474-8. 2008
    ..Transrectal ultrasound guided prostate needle biopsies are routinely performed to diagnose and stage prostate cancer. We prospectively evaluated the safety, morbidity, and complication rate...
  14. ncbi request reprint TP53 gene mutations as an independent marker for urinary bladder cancer progression
    Thorsten H Ecke
    Department of Urology, HELIOS Hospital, Bad Saarow, Germany
    Int J Mol Med 21:655-61. 2008
    ..We conclude that genetic analysis of TP53 can select patients at high risk of bladder tumour progression that should be followed closely and may benefit from early radical surgical procedures...
  15. ncbi request reprint Focus on urinary bladder cancer markers: a review
    T H Ecke
    HELIOS Hospital, Department of Urology, Bad Saarow, Germany
    Minerva Urol Nefrol 60:237-46. 2008
    ..Molecular staging of urological tumors will allow selecting cases that will require systemic treatment. It is necessary and important to integrate under the same objectives basic and clinical research...
  16. ncbi request reprint TP53 gene mutations in prostate cancer progression
    Thorsten H Ecke
    HELIOS Hospital, Department of Urology, Bad Saarow, Germany
    Anticancer Res 30:1579-86. 2010
    ..We assessed the predictive value of TP53 mutations and prostate-specific antigen (PSA) for tumor progression in prostate cancer (PCa) patients...
  17. ncbi request reprint Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer
    Thorsten H Ecke
    Department of Urology, Humaine Hospital, Pieskower Str 33, D 15526 Bad Saarow, Germany tho eckeghotmail com
    Anticancer Res 23:957-62. 2003
    ..TP53 mutations are frequently correlated with tumour development in bladder cancer. One function of TP53 is the suppression of apoptosis. We compared TPA expression and TP53 mutation analysis in tumour-free and bladder cancer patients...